Kouba

Researchers are conducting a prospective, multicenter, observational study called SAFRO 2202 ALG-Lung Cancer Registry to gather detailed information about lung cancer patients in Algeria. The study focuses on understanding the epidemiological, clinical, pathological, molecular, and treatment characteristics of adults diagnosed with lung cancer, including non-small cell lung cancer, small cell lung cancer, and carcinoid tumors. This research aims to fill gaps in real-world data on lung cancer management and outcomes across Algeria's public healthcare system. The study involves collecting data during routine clinical care at 21 public and university hospitals specialized in oncology and pulmonology. Eligible adults, diagnosed at inclusion or within the prior 12 months, have their demographic information, tumor histology, molecular profiles, staging, and treatment details recorded in a secure electronic case report form. Treatments include surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, but no additional study-specific procedures or visits are required. Participants' medical history, risk factors, treatment responses, and adverse events are monitored through standard care over at least 12 months. The study measures key outcomes such as tumor characteristics at diagnosis, treatment modalities, progression-free survival, treatment discontinuation time, and overall survival. This large-scale registry, enrolling around 1,500 patients yearly over 30 months, aims to support national health planning and improve lung cancer care in Algeria.

This research aims to improve understanding of rare autoinflammatory diseases (AID), which cause repeated inflammatory episodes without infection or cancer. The study focuses on hereditary periodic syndromes (monogenic AID) caused by gene mutations, as well as related polygenic or multifactorial AID like Behcet's disease, Still disease, Schnitzler's disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, spondyloarthritis, and Castleman disease. The goal is to gather detailed clinical and therapeutic data to expand knowledge of these rare conditions, which are often difficult to diagnose outside specialized centers. Participants will be enrolled in the AIDA international registry, which uses a secure online platform to collect retrospective and prospective information. Data collected include demographics, genetics, clinical features, laboratory and radiologic results, treatments, and socioeconomic impact. The registry covers multiple specific AID types and will track patients over at least 10 years through routine clinical visits usually every 3-6 months. The platform supports data sharing and analysis to identify disease patterns, treatment responses, and long-term outcomes. During the study, patients' medical records will be regularly updated with clinical and laboratory data. Researchers will analyze changes in patient numbers and disease characteristics over time. The registry also aims to foster international collaboration, improve early diagnosis, assess quality of life and socioeconomic effects, and support future research and clinical trials. Patient data privacy is maintained by using pseudonyms and complying with data protection laws throughout the study.

Researchers are studying the outcomes of pregnancies that happened before the diagnosis of systemic lupus erythematosus (SLE) in women who were later diagnosed with this condition. The study focuses on understanding maternal and fetal health during these pregnancies and examining signs of SLE that may have been present before or during pregnancy. It also aims to assess how severe the disease was at the time it was diagnosed using standard criteria. The study collects information from medical records and patient interviews, focusing on all pregnancies before and after the SLE diagnosis. For living participants, data is gathered through questionnaires about obstetrical events prior to diagnosis. For deceased patients, medical records are reviewed. Researchers will also collect available data on body measurements, biological, immunological, and kidney tissue findings before and after diagnosis. Disease activity and severity after diagnosis will be assessed using recommended tools. Participants will be evaluated from the start of each pregnancy and followed up to three months after childbirth. The study measures include the prevalence of pregnancy-related events before SLE diagnosis, severity of the disease at diagnosis, and pregnancy outcomes before and after SLE diagnosis. The study is observational and retrospective, focusing on collecting and analyzing past pregnancy and health information to better understand the relationship between pregnancy and SLE development.

Researchers are studying the use and outcomes of a pertuzumab biosimilar in patients with HER2-positive breast cancer. The study observes two groups: patients receiving neoadjuvant treatment before surgery and those receiving first-line treatment for metastatic breast cancer. The aim is to understand real-world treatment patterns and assess clinical outcomes such as pathological complete response, disease-free survival, progression-free survival, overall survival, treatment response, and safety. This is a non-interventional, prospective, multicenter observational study including about 1,000 patients, split evenly between the two groups. Patients receive pertuzumab biosimilar as part of routine care in either the neoadjuvant or first-line metastatic setting. The study does not involve assigning treatments but monitors patients receiving standard care in these settings. During up to 36 months of follow-up, participants' treatment use, therapy lines, duration, and prescribing context are tracked. Researchers assess responses to treatment using various methods and monitor safety by recording adverse events. The study collects data on clinical outcomes and treatment patterns to better understand the effectiveness and tolerability of the pertuzumab biosimilar in everyday medical practice.

Researchers are conducting an observational study to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer in Algeria. The study also aims to analyze how gastric cancer is diagnosed and treated across participating oncology departments. This non-interventional, descriptive, cross-sectional study gathers both prospective and retrospective data from about 1,000 patients with confirmed gastric cancer. Data collection involves reviewing medical records and brief patient interviews lasting around 30 minutes. All collected information will be anonymized and used exclusively for research. The study does not involve any treatments or interventions but focuses on documenting diagnostic and management practices for gastric cancer in Algeria. Participants will provide informed consent, and data will be gathered during a single visit. Researchers will collect demographic, sociological, epidemiological, clinical, and evolutionary characteristics of patients at baseline. The study also monitors diagnostic approaches and treatment strategies. Patient privacy and data confidentiality are maintained throughout the research process.

Researchers are describing the demographic, epidemiological, clinical, and outcome characteristics of patients diagnosed with prostate cancer in Algeria. The study also analyzes the diagnostic methods and treatment approaches used for managing these patients. This is a descriptive, cross-sectional clinical study including patients with histologically or biologically confirmed prostate cancer. The study plans to enroll 500 patients who are being followed in participating oncology centers. Data collection involves reviewing medical records and conducting structured patient interviews lasting approximately 30 minutes. A standardized electronic case report form is used to ensure data completeness and accuracy. Information gathered includes sociodemographic details, medical history, disease characteristics, diagnostic tests performed, and treatments implemented. Participants are evaluated at the initial visit with assessments including socio-demographic factors, personal and family cancer history, environmental and occupational exposures, smoking and alcohol use, initial symptoms, and diagnosis circumstances. The International Prostate Symptom Score (IPSS) and disease status are also recorded. All collected data is anonymized and used solely for research. The study focuses on baseline characteristics without interventional treatments or long-term follow-up described.

Researchers are evaluating how well oral vinorelbine works for treating women with advanced breast cancer. This study includes women who have either already received this treatment between 2011 and 2020 or who are currently starting it. It is an international, multicenter study that observes patients without adding extra medical procedures beyond routine cancer care. The study follows participants for up to two years to assess their progression-free survival and quality of life. The study consists of two groups: a retrospective group of patients who began oral vinorelbine treatment in the past and a prospective group including patients starting treatment now. Oral vinorelbine is given weekly, beginning with a dose of 60 mg/m² of body surface area for three weeks, then increasing to 80 mg/m² weekly. The prospective group will also complete questionnaires about their quality of life and work productivity during the study period. Participants will be monitored through their regular oncology visits with no additional study-related procedures required. Researchers will collect data on treatment outcomes, quality of life, and patient-reported experiences. The main outcome measured is the progression-free survival rate over two years. The total observation period lasts up to two years following the start of treatment for the latest enrolled patients.